CSL Limited

CSL Limited is an Australian-listed biopharmaceutical company whose businesses supply plasma-derived therapies, influenza vaccines, and treatments in iron deficiency and nephrology. Originating as a government laboratory established in 1916, it became a publicly traded company in 1994. CSL reports in US dollars and operates internationally through CSL Behring, CSL Seqirus and CSL Vifor. ^[1][1][3][4]

Origins and public listing

The Australian government established the Commonwealth Serum Laboratories in 1916 to address domestic health needs during the First World War. Its early public-health role included making medical products available in Australia; CSL identifies insulin, penicillin and vaccines among the products it supplied over subsequent decades. The organisation was initially carried on within the Commonwealth Department of Health. In 1961, its activities were placed in a statutory commission, the Commonwealth Serum Laboratories Commission. ^[1][4]

A sequence of legal changes preceded privatisation. The commission became a public company limited by shares on 1 April 1991, initially named Commonwealth Serum Laboratories Limited; the name changed to CSL Limited on 7 October 1991. The Commonwealth disposed of its shares through a public float on 3 June 1994. CSL states that its ordinary shares have traded on the Australian Securities Exchange under the code CSL since 30 May 1994. The distinction between the start of trading and the date of the public float accounts for the two dates appearing in its shareholder information. ^[1][4]

Privatisation changed CSL’s financing and ownership structure, rather than its underlying origin as a public-health producer. Shareholders acquired claims on a commercial company whose earnings would depend on product sales, manufacturing, research and acquisitions. CSL subsequently expanded its activities beyond Australia. A significant step came in March 2004, when it completed the acquisition of Aventis Behring’s plasma therapeutics business and combined it with ZLB Bioplasma to form ZLB Behring. That transaction enlarged the plasma-products business from which the present CSL Behring operation developed. ^[5]

Further acquisitions broadened the group’s product mix. In 2015, CSL completed the purchase of Novartis’s global influenza vaccine business and announced its integration with its existing bioCSL operation. In 2022, CSL obtained the regulatory clearances needed to complete its acquisition of Swiss company Vifor Pharma, adding businesses focused on iron deficiency and kidney care. These transactions help explain why CSL’s present activities span distinct therapeutic markets rather than a single medicine or vaccine category. ^[6][7]

Businesses and sources of revenue

CSL reports three operating segments. **CSL Behring** manufactures, markets and distributes plasma products, gene therapies and recombinant therapies. **CSL Seqirus** concentrates predominantly on influenza-related products and also provides pandemic services to governments. **CSL Vifor** makes and markets products in iron deficiency and nephrology. The company reports centrally managed research and development separately from those operating segments, as well as certain group-wide administrative functions. Segment results therefore do not, by themselves, represent the consolidated company’s profit. ^[3]

The plasma business links collection, manufacturing and commercialisation. Collected plasma is a raw material for a range of therapies, while manufacturing capacity and product yields influence the quantity of medicine that can be supplied from it. CSL identifies immunoglobulin therapies as an important part of this business. Its financial statements report US$6.248 billion of immunoglobulin revenue in the year ended 30 June 2026, alongside revenue from albumin, haemophilia, hereditary angioedema and peri-operative bleeding products. The categories describe sources of revenue, not separate publicly traded companies. ^[8][9]

Seqirus has a different demand pattern because it sells influenza vaccines and provides pandemic-related services. Its FY2026 revenue categories included adjuvanted egg-based vaccines, cell-culture vaccines and other egg-based vaccines, as well as pandemic reservation fees and pre-pandemic sales. Separating these categories matters when reading results: government preparedness payments and sales associated with pandemic planning need not move in the same way as routine seasonal vaccine sales. CSL’s segment disclosure identifies both vaccine products and government pandemic services within Seqirus. ^[3][9]

Vifor’s reported categories illustrate another distinction. In FY2026, CSL disclosed revenue from dialysis nephrology, non-dialysis nephrology and iron products, among other items. Those markets have different products and commercial conditions from either plasma therapies or influenza vaccines. Accordingly, changes in one part of CSL’s portfolio may be partly offset—or compounded—by changes elsewhere. The three-segment structure gives readers a way to examine that variation instead of treating total group revenue as a uniform measure of demand. ^[3][9]

Financial reporting and FY2026 results

CSL’s financial year ends on 30 June. Although the parent company is incorporated and domiciled in Australia and its ordinary shares trade locally, it presents its consolidated financial statements in **US dollars**. The FY2026 report says this reflects both pharmaceutical-industry reporting practice and the predominant currency of the group’s worldwide sales and operating expenses. Figures in its accounts should therefore not be read as Australian-dollar amounts unless expressly identified as such. The FY2026 financial report states that it was prepared under Australian Accounting Standards and International Financial Reporting Standards. ^[10]

For the year ended 30 June 2026, CSL reported total operating revenue of **US$15.797 billion**, compared with US$15.558 billion in FY2025. Its three businesses reported FY2026 revenue of US$11.387 billion for Behring, US$2.031 billion for Seqirus and US$2.379 billion for Vifor. Revenue measures sales and other operating income; it is not the amount remaining after production costs, research spending, financing costs and tax. The segment figures are useful for understanding the relative scale of CSL’s activities, with Behring accounting for the largest portion of reported revenue that year. ^[2][8]

The distinction between statutory earnings and adjusted measures was particularly important in FY2026. CSL reported a **net loss after tax attributable to owners of US$2.579 billion**, compared with a US$3.002 billion profit in FY2025. It also disclosed *underlying NPATA* of US$3.098 billion for FY2026. NPATA is an adjusted profit measure and should not be treated as interchangeable with statutory net profit. CSL’s results included substantial restructuring and impairment expenses: its segment note records US$7.923 billion of such expenses for FY2026, which were not allocated to individual segment operating results. The differing profit measures answer different questions about the reported year. ^[2][3]

Cash flow is another separate measure. CSL reported **US$3.512 billion in cash flow from operations** for FY2026. Operating cash flow records cash generated by operating activities under the company’s reporting definitions; it is neither the same as revenue nor a reversal of the statutory loss. Comparing it with profit requires attention to non-cash charges, working capital and other accounting adjustments. In FY2026, the large impairment expenses are especially relevant to understanding why the reported loss and operating cash flow moved differently. ^[8][3]

Shares, dividends and shareholders

CSL’s ordinary shares trade on the ASX under **CSL**. The company also has a sponsored American depositary receipt programme traded over the counter in the United States under **CSLLY**; CSL’s investor information states that two depositary receipts represent one ordinary share. These are different forms of exposure to the same underlying company, not listings of separate operating businesses. CSL reported 478,911,979 ordinary shares on issue at 30 June 2026. ^[1][4]

Dividends are distributions determined by the board, rather than a fixed entitlement to a proportion of annual revenue. For FY2026, CSL reported total dividends of **US$2.92 per ordinary share**, including a final dividend of US$1.62 per share. The company stated that the final dividend was unfranked. A dividend per share should also be distinguished from the group-wide cash cost of a distribution, which depends on the number of eligible shares. CSL’s FY2026 report separately recorded completion of an **A$1 billion share buy-back programme**; the Australian-dollar designation on that figure differs from the US-dollar presentation of its main financial results. ^[8][11]

CSL’s shareholder information describes restrictions associated with significant foreign shareholdings under legislation stemming from its privatisation. In particular, the company’s constitution limits the counting of certain votes relating to the appointment or removal of designated directors. These provisions are part of CSL’s ownership framework and should not be confused with a general prohibition on foreign ownership of its publicly traded shares. ^[4]

Business and reporting risks

CSL’s activities expose it to risks that differ across its portfolio. Developing medicines involves scientific, clinical-trial and intellectual-property uncertainty. Manufacturing biological products and collecting plasma require quality systems and regulatory compliance. Changes in reimbursement, competition or expected product sales can also affect the economic value assigned to acquired assets. CSL identifies research and development, regulation, clinical trials and intellectual property among the risks it assesses at group level. ^[12]

The FY2026 result provides an example of how business assumptions can affect financial statements. CSL said that its impairments reflected factors including changes in commercial outlook, expected timing of generic competition, regulatory developments, market conditions and assumptions about site use. An impairment reduces the accounting carrying value of an asset when the applicable test indicates that value is no longer supportable; it need not represent an equivalent cash payment in the year recognised. Readers assessing CSL’s performance therefore need to distinguish recurring product revenue and cash generation from restructuring charges, asset write-downs and management-defined underlying results. ^[3][13]